1 / 19

SWEDISH-AMERICAN LIFE SCIENCE SUMMIT August 19-21, 2009

SWEDISH-AMERICAN LIFE SCIENCE SUMMIT August 19-21, 2009. An Introduction to Affibody. Second generation antibody mimetics company. Affibody ® Technology – Proprietary Triple Helical Platforms. Affibody ® Platform. Albumod TM Platform. N. N. 6 kDa . 5 kDa .

jack
Download Presentation

SWEDISH-AMERICAN LIFE SCIENCE SUMMIT August 19-21, 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SWEDISH-AMERICAN LIFE SCIENCE SUMMIT August 19-21, 2009

  2. An Introduction to Affibody Second generation antibody mimetics company

  3. Affibody® Technology – Proprietary Triple Helical Platforms Affibody® Platform AlbumodTM Platform N N 6 kDa 5 kDa Two proprietary platforms – versatile business model

  4. More than 20 approved therapeutic mAbs Blockbusters such as Rituxan®, Remicade®, Herceptin®, Avastin®, Humira®, Erbitux®, and Synagis® Therapeutic mAb revenue projected at above USD 30bn in ’09 Expected 5-yr Sales CAGR >10% Large pipeline of products in late-stage development The Antibody Opportunity Monoclonal Antibody (mAb) Therapeutic mAbs Monoclonal antibodies are reshaping the industry

  5. Affibody® Molecules – Next Generation Antibody • Small size (1/25th the size of a mAb) • High selectivity and affinity (high potency) • Rapid and reversibly folding (extreme stability) • Flexible low cost production (peptide synthesis or recombinant production) • Flexible engineering and formatting (modified properties and formats) Affibody® molecule6 kDa Monoclonal Antibody (mAb)150 kDa A fraction of the size packed with the same power

  6. 6 h p.i. 24 h p.i. 6 h p.i. 24 h p.i. Anti-HER2 Affibody® Molecule vs. Trastuzumab 124I-Trastuzumab, N87 Xenografted mice mAb • High background • Extended exposure of non-target organs 124I-Anti-HER2 Affibody® Molecule, N87 Xenografted mice Affibody® Molecule • Rapid high tumor uptake • Improved potency / side-effect ratio When you can see it you can treat it

  7. Affibody® Technology – Proprietary Triple Helical Platforms Affibody® Platform AlbumodTM Platform N N 6 kDa 5 kDa Two proprietary platforms – versatile business model

  8. Potency – sustained efficacy Economy – reduced dosage Safety – avoid high peak blood concentrations Life cycle management / Biosuperiors Half Life from Minutes to Days (primate) 5-fold Higher Dose on Tumor (mouse) AlbumodTM Platform – Extending Half-Life Half-life: from hours to days  increased potency

  9. Therapeutics and Imaging Portfolio Overview Clinical Development Program Preclinical Research TargetSelection LeadIdentification Phase I LeadOptimization Phase II Preclinical Phase III Oncology Anti-HER2Affibody® Molecule Breast Cancer, Phase I/IIa study approved, exploratory clinical data Bladder Cancer, Phase I study approved Breast and Bladder Cancer, pre-clinical efficacy Anti-EGFRAffibody® Molecule Head and Neck Cancer, ready for development Anti-PDGFRβAffibody® Molecule Cancer, ready for development Anti-PSMAAffibody® Molecule Prostate Cancer Hematology Long-acting G-CSF Neutropenia,PK data Inflammation and autoimmune Therapeutics Imaging Undisclosed Undisclosed

  10. HER2 Program(Imaging and Therapy)

  11. Anti-HER2 Affibody® Molecule Imaging Opportunity Breast Cancer • Exploratory clinical data available • Phase I dose finding study approved Bladder Cancer Imaging • Exploratory application approved Safety and Immunology • Repeated dose tox demonstrated the molecule to be safe and well tolerated • Non-immunogenic after repeated dosing in rat Clinical Development Plan • Phase I dose finding study (27 patients, 6 months) • Phase III confirmatory study (150-200 patients, 9 months) Breast Cancer patient with brain metastasis Short time to market – limited number of patients

  12. Tumor Tumor 17-AAGtreated CORONAL TRANSVERSAL HER2 Imaging – Novel Diagnostic Applications Global HER2 status (2 h p.i., PET/CT) Monitoring therapy response (4 h p.i., SPECT) Orlova, A., et al. (2007) Cancer Research, 67: 2178-86. Use cases demonstrated not possible with current standard (biopsy)

  13. Trends in Oncology mAb Therapy • Antibody-drug conjugation (payloads) • T-DM1 (Herceptin + payload), Ph III, Genentech/ImmunoGen • Genentech plans to file 1-2 INDs on payload drugs annually • SGN-35 (CD30 + payload), Ph III, Seattle Genetics • Focus on effector functions • e.g. Xencor, Macrogenics, Glycart, Micromet – BiTE, Merrimack – HER2/HER3 The Affibody® molecule is an optimal payload carrier

  14. PE38 toxin Anti-HER2 Affibody® Molecule – Payload Therapeutics Therapeutic Efficacy - HER2 Affibody® Toxin Fusion Protein Tumor volume BT474 Xenografts Saline Toxin fusion 250 g/kg HER2 Affibody® Toxin Fusion shrinks solid tumors

  15. Long-acting G-CSF(Therapy)

  16. NFS-60 proliferation assay Long-acting G-CSF – A Biosuperior Opportunity Retained Specific Activity 10-Fold Increased Circulation Time A single i.v. injection of equimolar amounts of G-CSF-ABD0 fusion (n=5) or G-CSF (Neupogen®) (n=2) to rats 10x increased circulation time and fully retained activity

  17. Achievements During 2009 • Therapeutics • Preclinical efficacy demonstrated in collaboration with NCI (HER2) • Prolonged circulation time with retained activity demonstrated (G-CSF) • Medical Imaging • Approved Swedish Bladder Cancer Imaging Study • Approved German Breast Cancer Imaging Study • Business Development • Collaboration with Biovitrum • New deals currently negotiated Considerable achievements during 2009

  18. The Value of Antibody Mimetics – Example of Deals Amgen acquired Avidia for $290m (2006) • Amgen bought Avidia to get access to a small scaffold protein, based on only early preclinical data. Pfizer bought BioRexis for an unknown amount (2006) • The acquisition gave Pfizer proprietary rights to transferin as a scaffold, and for halflife extension of peptides. Only preclinical data were available at the time of purchase. GSK acquired Domantis for $455m (2006) • Domantis was a domain antibody scaffold company. Only preclinical data were available at the time of purchase. BMS bought Adnexus for $430 million (2007) • Adnexus had proprietary rights to fibronectin as a scaffold, and for halflife extension of peptides. Only preclinical data were available at the time of purchase. Significant values have been realized by similar technologies

  19. Investment Case • Balanced portfolio – therapeutics and diagnostics • From imaging to therapy in oncology • Excellent payload carrier • Growing revenue stream • Primarily driven by royalty revenue • Validating collaborations Positioned to capitalize on the next wave of antibody therapeutics

More Related